PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.18%
Negative revenue growth while CRON.TO stands at 17.21%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-13.34%
Negative gross profit growth while CRON.TO is at 54.40%. Joel Greenblatt would examine cost competitiveness or demand decline.
-340.87%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-340.87%
Negative operating income growth while CRON.TO is at 22.87%. Joel Greenblatt would press for urgent turnaround measures.
-148.50%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-145.28%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-145.28%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.27%
Slight or no buybacks while CRON.TO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.36%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-32.18%
Negative OCF growth while CRON.TO is at 1.55%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
3.33%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
1118.33%
5Y CAGR of 1118.33% while CRON.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
654.32%
3Y revenue/share CAGR similar to CRON.TO's 663.95%. Walter Schloss would assume both companies experience comparable short-term cycles.
-339.33%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-2397.94%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-604.60%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-315.13%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-278.03%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-165.58%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
3215.35%
Equity/share CAGR of 3215.35% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2681.11%
5Y equity/share CAGR is in line with CRON.TO's 2482.42%. Walter Schloss would see parallel mid-term profitability and retention policies.
137.62%
Below 50% of CRON.TO's 1524.82%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.81%
AR growth is negative/stable vs. CRON.TO's 17.02%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
35.48%
Inventory growth well above CRON.TO's 23.42%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.87%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
0.31%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
7.25%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
10.80%
We increase R&D while CRON.TO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
20.12%
We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.